Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MNRP1685A · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| A | EXPERIMENTAL | - |
| B | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| bevacizumab | DRUG | Intravenous repeating dose |
| MNRP1685A | DRUG | Escalating intravenous dose |
| paclitaxel | DRUG | Intravenous repeating dose |
Inclusion Criteria: * Adequate hematologic and end organ function * Evaluable disease or measurable disease per Response Evaluation Criteria In Solid Tumors (RECIST) * Agreement to use an effective form of contraception for the duration of the study Inclusion Criteria Unique to Arm A: * Histologi...
MNRP1685A is an investigational small molecule being studied for the treatment of locally advanced or metastatic solid tumors. It is in Phase 1 clinical development and has not been approved by regulatory authorities. Two completed trials have evaluated it, both in patients with solid cancers.
MNRP1685A is being developed by Roche Holding AG, which trades under the ticker RHHBY. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with solid tumors.
MNRP1685A is in Phase 1 clinical development. Both of its clinical trials have been completed, and the drug remains investigational. It has not received approval from the FDA or other regulatory agencies for any indication.
MNRP1685A has been studied in two completed Phase 1 trials. NCT00747734 evaluated the drug alone in patients with locally advanced or metastatic solid tumors, enrolling 35 participants. NCT00954642 tested it in combination with bevacizumab, with or without paclitaxel, in 24 patients with the same condition.
No alternative names for MNRP1685A have been disclosed. The drug is identified solely by its code name MNRP1685A in clinical trial records and development documentation.